Skip to main content

Nanogen Completes Acquisition of SynX

NEW YORK, April 21 (GenomeWeb News) - Nanogen of San Diego, Calif., today announced the closing of its all-stock acquisition of SynX Pharma of Toronto.

 

The company will issue approximately 1.6 million shares of its common stock to SynX shareholders at an exchange ratio of 0.123 Nanogen shares per each SynX common share. Additionally, Nanogen acquired CA $3.5 million ($2.6 million) of subordinated secured debentures of SynX in exchange for 300,000 shares of its common stock.

 

SynX is now a wholly owned subsidiary of Nanogen, nearly three months after the acquisition was first announced.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.